Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) CAO Michael Gunnar Knel

Shares of Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) hit a new 52-

TD Cowen analyst Charles Rhyee maintains Charles River (NYSE:CRL) with a Buy and raises the price

Explore how Charles River's (CRL) revenue from international markets is changing and the resulting i

Morgan Stanley analyst Ricky Goldwasser maintains Charles River (NYSE:CRL) with a Overweight and

Wall Street analysts upgraded AVITA, Etsy, Unity, and raised target prices for these stocks. See wha

RBC Capital analyst Ryan Halsted maintains Charles River (NYSE:CRL) with a Outperform and raises

Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and ra

Wall Street analysts change outlook on top names. See all rating changes, upgrades, downgrades and i

Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits o

Charles River Laboratories International NYSE: CRL reported second-quarter results that exceeded its

JP Morgan analyst Casey Woodring upgrades Charles River (NYSE:CRL) from Neutral to Overweight and

Gold posts its biggest one-day gain since February and the Dow sets a record as Iran deal hopes cool

Charles River Laboratories International, Inc. (CRL) Q2 2026 Earnings Call Transcript

Charles River (CRL) stock jumped after Q2 earnings beat estimates and the company raised its full-ye

Charles River beats Q2 earnings and revenue estimates, raises 2026 outlook and gains 7.9% in pre-mar

Here is how Charles River Laboratories (CRL) and Curaleaf Holdings, Inc. (CURLF) have performed comp

Charles River Laboratories has rebounded 40% from last year, driven by improved organic revenue and

Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in t

Charles River Laboratories (CRL) came out with quarterly earnings of $3.02 per share, beating the Za

US stocks rise, Wynn Resorts beat earnings expectations, share price jumps 10.9%. Other companies re

Contract drug developer Charles River Laboratories on Wednesday raised its annual profit forecast af

Charles River (NYSE:CRL) raises FY2026 Adj EPS guidance from $10.80-$11.30 to $11.15-$11.45 vs $11.1

Charles River (NYSE:CRL) reported quarterly earnings of $3.02 per share which beat the analyst conse

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Second-Quarter 2026 Financi

California State Teachers Retirement System lifted its stake in shares of Charles River Laboratories

Avidity Partners Management LP bought a new position in shares of Charles River Laboratories Interna

CRL is set to report Q2 results on Aug. 5 as investors watch segment demand, divestitures, and wheth

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings

U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting bet

Epoch Investment Partners Inc. reduced its holdings in Charles River Laboratories International, Inc

On July 23, 2026, Charles River Laboratories International Inc (CRL) shares rose 4.8% to a current p

IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-wei

Fifth Third Bancorp grew its stake in shares of Charles River Laboratories International, Inc. (NYSE

Wall Street analysts change outlook on top names. Complete view of analyst rating changes including

Mizuho analyst Ann Hynes maintains Charles River (NYSE:CRL) with a Neutral and raises the price t

Morgan Stanley analyst Ricky Goldwasser maintains Charles River (NYSE:CRL) with a Overweight and

Top Wall Street analysts upgraded MITT & MFA. See ratings & price targets for these stocks.

Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J

Morgan Stanley analyst Ricky Goldwasser upgrades Charles River (NYSE:CRL) from Equal-Weight to Ov

CLSA analyst Michael Luo upgrades Charles River (NYSE:CRL) from Hold to Outperform and raises the

Partnership showcases a forward-looking collaboration model that highlights advanced testing experti

Charles River Laboratories (NYSE: CRL) beat Q1 earnings estimates but lowered its FY2026 forecast. A

Barclays analyst Luke Sergott maintains Charles River (NYSE:CRL) with a Overweight and raises the

Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and ra